ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)
Summary
This is an open label, multi-centre, non-interventional post-marketing surveillance.
Description
This is an open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety of ALTARGO(retapamulin) treated in Korean patients according to the prescribing information.
ALTARGO is a trademark of the GlaxoSmithKline group of companies.
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Conditions
Skin Infections, Bacterial
Intervention
ALTARGO(retapamulin)
Location
GSK Investigational Site
Seoul
Korea, Republic of
138-736
Status
Not yet recruiting
Source
GlaxoSmithKline
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT01445600
- Information obtained from ClinicalTrials.gov on April 11, 2013
Medical and Biotech [MESH] Definitions
Central Nervous System Bacterial Infections
Bacterial infections of the brain, spinal cord, and meninges, including infections involving the perimeningeal spaces.
Central Nervous System Infections
Pathogenic infections of the brain, spinal cord, and meninges. DNA VIRUS INFECTIONS; RNA VIRUS INFECTIONS; BACTERIAL INFECTIONS; MYCOPLASMA INFECTIONS; SPIROCHAETALES INFECTIONS; fungal infections; PROTOZOAN INFECTIONS; HELMINTHIASIS; and PRION DISEASES may involve the central nervous system as a primary or secondary process.
Staphylococcal Skin Infections
Infections to the skin caused by bacteria of the genus STAPHYLOCOCCUS.
Pneumonia, Bacterial
Inflammation of the lung parenchyma that is caused by bacterial infections.
Bacterial Infections
Infections by bacteria, general or unspecified.
Clinical Trials
Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.
A study to evaluate the pharmacokinetics of Retapamulin Ointment, 1%, in pediatric subjects (2-24 months) with secondarily-infected traumatic lesions, secondarily-infected dermatoses, or i...
EU PV for Retapamulin-Prescribing
Retapamulin, a topical pleuromutilin antibiotic, is the first in a new class of topical antibiotics approved for human use. In the European Union (EU), retapamulin is approved for the tre...
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
The purpose of this study is to document the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with bacterial infections, including impetigo, folliculitis,...
The objective of this study is to evaluate the efficacy and safety of oral NXL103 vs. established treatment of acute bacterial infection in adults.
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
The purpose of this study is to determine the safety and efficacy of CEM-102 compared to Linezolid in the treatment of acute bacterial skin structure infections (ABSSIs).
PubMed Articles
Uncovering common bacterial skin infections.
ABSTRACT: The four most common bacterial skin infections are impetigo, erysipelas, cellulitis, and folliculitis. This article summarizes current information about the etiology, clinical presentation,...
Acute bacterial skin and skin structure infections (ABSSSIs), including cellulitis or erysipelas, major cutaneous abscesses, and wound infections, can be life-threatening and may require surgery and h...
Staphylococcus aureus skin infections represent a significant public health threat because of the emergence of antibiotic-resistant strains such as methicillin-resistant S. aureus (MRSA). As greater u...
Uncovering common bacterial skin infections.
Telavancin is an injectable lipoglycopeptide that is bactericidal in vitro against staphylococci, streptococci and vancomycin-susceptible enterococci. Telavancin inhibits bacterial cell wall synthesis...
